These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1270 related articles for article (PubMed ID: 22335009)

  • 21. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
    Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
    Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease.
    Miheller P; Muzes G; Zagoni T; Toth M; Racz K; Tulassay Z
    Dig Dis; 2006; 24(1-2):201-6. PubMed ID: 16699279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perianal complete remission with combined therapy (seton placement and anti-TNF agents) in Crohn's disease: a Brazilian multicenter observational study.
    Kotze PG; Albuquerque IC; da Luz Moreira A; Tonini WB; Olandoski M; Coy CS
    Arq Gastroenterol; 2014; 51(4):284-9. PubMed ID: 25591155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-TNF and fistulizing perianal Crohn's disease: use in clinical practice.
    Bourikas LA; Koutroubakis IE
    Curr Drug Targets; 2010 Feb; 11(2):187-97. PubMed ID: 19916954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
    Riis A; Martinsen TC; Waldum HL; Fossmark R
    Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete resolution of enterocolic fistulas with infliximab.
    Nunes J; Santos PM; Tavares L
    BioDrugs; 2010 Dec; 24 Suppl 1():28-30. PubMed ID: 21175233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
    Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
    Ong DE; Kamm MA; Hartono JL; Lust M
    J Gastroenterol Hepatol; 2013 Oct; 28(10):1595-9. PubMed ID: 23662928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report.
    van der Hagen SJ; Baeten CG; Soeters PB; Russel MG; Beets-Tan RG; van Gemert WG
    Dis Colon Rectum; 2005 Apr; 48(4):758-67. PubMed ID: 15750797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4+CD161+ T lymphocytes infiltrate Crohn's disease-associated perianal fistulas and are reduced by anti-TNF-α local therapy.
    Maggi L; Capone M; Giudici F; Santarlasci V; Querci V; Liotta F; Ficari F; Maggi E; Tonelli F; Annunziato F; Cosmi L
    Int Arch Allergy Immunol; 2013; 161(1):81-6. PubMed ID: 23257766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience.
    Oussalah A; Babouri A; Chevaux JB; Stancu L; Trouilloud I; Bensenane M; Boucekkine T; Bigard MA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Feb; 29(4):416-23. PubMed ID: 19035976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
    Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
    Kiss LS; Szamosi T; Molnár T; Miheller P; Lakatos L; Vincze A; Palatka K; Bartha Z; Gasztonyi B; Salamon A; Horváth G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovász BD; Végh Z; Golovics PA; Szathmári M; Papp M; Lakatos PL
    Orv Hetil; 2011 Sep; 152(36):1433-42. PubMed ID: 21865144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genital fistulas in female Crohn's disease patients.: clinical characteristics and response to therapy.
    de la Poza G; López-Sanroman A; Taxonera C; Marín-Jimenez I; Gisbert JP; Bermejo F; Opio V; Muriel A
    J Crohns Colitis; 2012 Apr; 6(3):276-80. PubMed ID: 22405162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human granulocyte-macrophage colony stimulating factor (sargramostim) as an alternative therapy for fistulizing Crohn's disease.
    Magno P; Jiménez CE; Ortiz Z; Torres EA
    P R Health Sci J; 2010 Mar; 29(1):60-5. PubMed ID: 20222336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
    Van Assche G; Vanbeckevoort D; Bielen D; Coremans G; Aerden I; Noman M; D'Hoore A; Penninckx F; Marchal G; Cornillie F; Rutgeerts P
    Am J Gastroenterol; 2003 Feb; 98(2):332-9. PubMed ID: 12591051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.